Sanofi Reported Earlier: Completed XTEND-Kids Phase 3 Study Strengthens Potential Of ALTUVIIIOTM To Redefine Expectations For Treatment Of Children <12 Years Of Age With Hemophilia A; Study Met Primary Endpoint Of Safety
The XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO as once-weekly prophylaxis in previously treated patients <12 years of age with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected in 74 children, with more than 50 children experiencing at least 50 exposure days, nearly a full year of treatment.
